Cabergoline versus levodopa monotherapy

Mov Disord. 2004 Jun;19(6):733-4; author reply 734-5. doi: 10.1002/mds.20032.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Comment

MeSH terms

  • Antiparkinson Agents / economics
  • Antiparkinson Agents / therapeutic use*
  • Cabergoline
  • Cost-Benefit Analysis
  • Ergolines / economics
  • Ergolines / therapeutic use*
  • Humans
  • Levodopa / economics
  • Levodopa / therapeutic use*
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / economics

Substances

  • Antiparkinson Agents
  • Ergolines
  • Levodopa
  • Cabergoline